Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：41
|
作者：
Doebele, R. [1 ]
Ahn, M. [2 ]
Siena, S. [3 ,4 ]
Drilon, A. [5 ]
Krebs, M. [6 ]
Lin, C. [7 ]
De Braud, F. [8 ]
John, T. [9 ]
Tan, D. [10 ]
Seto, T. [11 ]
Dziadziuszko, R. [12 ]
Arkenau, H. [13 ]
Barlesi, F. [14 ]
Rolfo, C. [15 ]
Wolf, J. [16 ]
Chow-Maneval, E. [17 ]
Multani, P. [17 ]
Cui, N. [18 ]
Riehl, T. [18 ]
Cho, B. C. [9 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea
[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy
[4] Univ Milan, Milan, Italy
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA
[6] Univ Manchester, Manchester, Lancs, England
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[9] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[10] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[11] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[12] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland
[13] Sarah Cannon Res Inst, London, England
[14] Aix Marseille Univ, AP HM, Marseille, France
[15] Antwerp Univ Hosp, Oncol Dept, Phase 1 Early Clin Trials Unit, Antwerp, Belgium
[16] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany
[17] Ignyta Inc, San Diego, CA USA
[18] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; entrectinib; ROS1 gene fusion;
D O I：
10.1016/j.jtho.2018.08.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA02.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
    Liu, Stephen V.
    Peeters, Marc
    Ahn, Myung-Ju
    Lin, Jessica J.
    Ohe, Yuichiro
    Yau, Chung Cheung Thomas
    Bordogna, Walter
    Osborne, Stuart
    Schwemmers, Sven
    Zeuner, Harald
    Goto, Koichi
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [32] Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
    Solomon, B. J.
    Martini, J-F.
    Ou, S-H. I.
    Chiari, R.
    Soo, R. A.
    Bearz, A.
    Li, S.
    Thurm, H.
    Lin, C-C.
    Riely, G. J.
    Bauer, T. M.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2018, 29 : 495 - 495
  • [33] Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
    Barlesi, F.
    Wolf, J.
    Ahn, M-J.
    Doebele, R. C.
    Paz-Ares, L.
    Rolfo, C.
    Siena, S.
    Seto, T.
    Ohe, Y.
    Ou, S. H. I.
    Krebs, M. G.
    Kapre, A.
    Piault-Louis, E.
    McCallum, S.
    Osborne, S.
    Aziez, A.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1391 - S1392
  • [34] Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer
    Wang, Jialei
    Zhao, Xinmin
    Zhang, Xin
    Chen, Hanlin
    Bao, Hairong
    Wu, Xianghua
    Wang, Huijie
    Bao, Hua
    Pang, Jiao
    Wang, Sha
    Tang, Haimeng
    Tang, Shiting
    Wu, Xue
    Shao, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Larotrectinib in TRK fusion-positive, metastatic non-small cell lung cancer (NSCLC) after treatment with entrectinib in a patient with a history of coronary artery disease
    Su, Derrick W.
    Pan, Janet
    Shahab, Nour
    Le, Hoang
    Malhotra, Kamini
    Patel, Tushar
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 6
  • [36] Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer.
    Lu, Shun
    Li, Ziming
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis
    Huo, Gengwei
    Song, Ying
    Chen, Xiongwen
    Chen, Peng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (04) : 839 - 848
  • [38] Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
    Lin, Jessica J.
    Cho, Byoung Chul
    Camidge, D. Ross
    Kim, Sang-We
    Solomon, Benjamin
    Dziadziuszko, Rafal
    Besse, Benjamin
    Goto, Koichi
    de langen, Adrianus Johannes
    Wolf, Jurgen
    Lee, Ki Hyeong
    Popat, Sanjay
    Springfeld, Christoph
    Nagasaka, Misako
    Felip, Enriqueta
    Yang, Nong
    Lu, Shun
    Kao, Steven
    Velcheti, Vamsidhar
    Cheema, Parneet
    Stopatschinskaja, Shanna
    Mehta, Minal
    Trone, Denise
    Ades, Felipe
    Calvet, Christophe Y.
    Drilon, Alexander
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [39] ROS1 positive Non-Small Cell Lung Cancer clinical case
    Silva, Sonia
    Feijo, Salvato
    MEDICINE, 2020, 99 (23)
  • [40] Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
    Doebele, R.
    Perez, L.
    Trinh, H.
    Martinec, M.
    Martina, R.
    Riehl, T.
    Krebs, M.
    Meropol, N.
    Wong, W.
    Crane, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S392 - S392
12345